490 related articles for article (PubMed ID: 12097567)
1. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
Browning MJ; Huang AS; Reiss CS
J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
[TBL] [Abstract][Full Text] [Related]
3. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
Marsac D; Puaux AL; Rivière Y; Michel ML
Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
[TBL] [Abstract][Full Text] [Related]
4. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
Wong SB; Siliciano RF
J Virol; 2005 Feb; 79(3):1701-12. PubMed ID: 15650195
[TBL] [Abstract][Full Text] [Related]
5. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
6. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
7. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
[TBL] [Abstract][Full Text] [Related]
8. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
[TBL] [Abstract][Full Text] [Related]
9. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.
Kuate S; Stahl-Hennig C; Stoiber H; Nchinda G; Floto A; Franz M; Sauermann U; Bredl S; Deml L; Ignatius R; Norley S; Racz P; Tenner-Racz K; Steinman RM; Wagner R; Uberla K
Virology; 2006 Jul; 351(1):133-44. PubMed ID: 16616946
[TBL] [Abstract][Full Text] [Related]
12. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.
Yokomaku Y; Miura H; Tomiyama H; Kawana-Tachikawa A; Takiguchi M; Kojima A; Nagai Y; Iwamoto A; Matsuda Z; Ariyoshi K
J Virol; 2004 Feb; 78(3):1324-32. PubMed ID: 14722287
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.
Qiu JT; Song R; Dettenhofer M; Tian C; August T; Felber BK; Pavlakis GN; Yu XF
J Virol; 1999 Nov; 73(11):9145-52. PubMed ID: 10516021
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
17. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses.
Marques ET; Chikhlikar P; de Arruda LB; Leao IC; Lu Y; Wong J; Chen JS; Byrne B; August JT
J Biol Chem; 2003 Sep; 278(39):37926-36. PubMed ID: 12824194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
